1. Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway.
   Wilson BJ, Giguère V.
   Mol Cancer. 2008 Jun 4;7:49. Pubmed
2. Meta-analysis of breast cancer microarray studies in conjunction with conserved cis-elements suggest patterns for coordinate regulation.
   Smith DD, Saetrom P, Snove O Jr, Lundberg C, Rivas GE, Glackin C, Larson GP.
   BMC Bioinformatics. 2008 Jan 28;9(1):63 Pubmed
3. CD200: a putative therapeutic target in cancer.
   Moreaux J, Veyrune JL, Reme T, De Vos J, Klein B.
   Biochem Biophys Res Commun. 2008 Feb 1;366(1):117-22. Epub 2007 Dec 4. Pubmed
4. Identification of novel pathway partners of p68 and p72 RNA helicases through Oncomine meta-analysis.
   Wilson BJ, Giguère V.
   BMC Genomics. 2007 Nov 15;8:419. Pubmed
5. Cellular functions of 14-3-3zeta in apoptosis and cell adhesion emphasize its oncogenic character.
   Niemantsverdriet M, Wagner K, Visser M, Backendorf C.
   Oncogene. 2008 Feb 21;27(9):1315-9. Epub 2007 Aug 20. Pubmed
6. Tenascin-W is a novel marker for activated tumor stroma in low-grade human breast cancer and influences cell behavior
   Degen M, Brellier F, Kain R, et al.
   Cancer Research 67 (19): 9169-9179 Oct 1 2007 Pubmed
7. Breast cancer molecular signatures as determined by SAGE: correlation with lymph node status
   Abba MC, Sun H, Hawkins KA, et al.
   Molecular Cancer Research 5 (9): 881-890 Sep 2007 Pubmed
8. The ubiquitin-conjugating enzyme E2-EPF is overexpressed in primary breast cancer and modulates sensitivity to topoisomerase II inhibition
   Tedesco D, Zhang JH, Trinh L, et al.
   Neoplasia 9 (7): 601-u4 Jul 2007 Pubmed
9. Integrative genomic analysis of phosphatidylinositol 3 ‘-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer
   Zhang L, Huang J, Yang N, et al.
   Clinical Cancer Research 13 (18): 5314-5321 Part 1 Sep 15 2007 Pubmed
10. The la autoantigen is a malignancy-associated cell death target that is induced by DNA-damaging drugs
    Al-Ejeh F, Darby JM, Brown MP
    Clinical Cancer Research 13 (18): 5509s-5518s Part 2 Suppl. S Sep 15 2007 Pubmed
11. UTRN on chromosome 6q24 is mutated in multiple tumors
    Li Y, Huang J, Zhao YL, et al.
    Oncogene 26 (42): 6220-6228 Sep 13 2007 Pubmed
12. Expression of interleukin-13 receptor alpha 2 in glioblastoma multiforme: Implications for targeted therapies
    Jarboe JS, Johnson KR, Choi Y, et al.
    Cancer Research 67 (17): 7983-7986 Sep 1 2007 Pubmed
13. Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth
    O’Neill CF, Urs S, Cinelli C, et al.
    American Journal of Pathology 171 (3): 1023-1036 Sep 2007 Pubmed
14. Mining gene expression profiles: expression signatures as cancer phenotypes
    Joseph R. Nevins and Anil Potti
    Nature Reviews/Genetics. 2007 Aug vol 8:601 NPG
15. Protein 4.1B suppresses prostate cancer progression and metastasis
    Wong SY, Haack H, Kissil JL, et al.
    Proceedings of The National Academy of Sciences of The United States of America 104 (31): 12784-12789 Jul 31 2007 Pubmed
16. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth
    Wang QB, Li W, Liu XS, et al.
    Molecular Cell 27 (3): 380-392 Aug 3 2007 Pubmed
17. Pre- and post-initiation chemoprevention activity of 2-alkyl/aryl selenazolidine-4(R)-carboxylic acids against tobacco-derived nitrosamine (NNK)-induced lung tumors in the A/J mouse
    Franklin MR, Moos PJ, El-Sayed WM, et al.
    Chemico-Biological Interactions 168 (3): 211-220 Jul 20 2007 Pubmed
18. Evidence for systems-level molecular mechanisms of tumorigenesis
    Hernandez P, Huerta-Cepas J, Montaner D, et al.
    BMC Genomics 8: Art. No. 185 Jun 20 2007 Pubmed
19. Large-scale integration of cancer microarray data identifies a robust common cancer signature
    Xu L, Geman D, Winslow RL
    BMC Bioinformatics 8: Art. No. 275 Jul 30 2007 Pubmed
20. Characterization of protein-interaction networks in tumors
    Platzer A, Perco P, Lukas A, et al.
    BMC Bioinformatics 8: Art. No. 224 Jun 27 2007 Pubmed
21. Alterations of the HBP1 transcriptional repressor are associated with invasive breast cancer
    Paulson KE, Rieger-Christ K, McDevitt NA, et al.
    Cancer Research 67 (13): 6136-6145 Jul 1 2007 Pubmed
22. Endothelin receptor type B counteracts tenascin-C-induced endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization
    Lange K, Kammerer M, Hegi ME, et al.
    Cancer Research 67 (13): 6163-6173 Jul 1 2007 Pubmed
23. Metastasis-associated protein 1 transgenic mice: A new model of spontaneous B-Cell lymphornas
    Bagheri-Yarmand R, Balasenthil S, Gururaj AE, et al.
    Cancer Research 67 (15): 7062-7067 Aug 1 2007 Pubmed
24. Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data
    Kim B, Lee HJ, Choi HY, et al.
    Cancer Research 67 (15): 7431-7438 Aug 1 2007 Pubmed
25. DGEM - A Microarray gene expression database for primary human disease tissues
    Xia YN, Campen A, Rigsby D, et al.
    Molecular Diagnosis & Therapy 11 (3): 145-149 2007 Pubmed
26. Expression of Ral GTPases, their effectors, and activators in human bladder cancer
    Smith SC, Oxford G, Baras AS, et al.
    Clinical Cancer Research 13 (13): 3803-3813 Jul 1 2007 Pubmed
27. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes
    Warnat P, Oberthuer A, Fischer M, et al.
    BMC Cancer 7: Art. No. 89 May 25 2007 Pubmed
28. CKAP2 is a spindle-associated protein degraded by APC/C-cdh1 during mitotic exit
    Seki A, Fang GW
    Journal of Biological Chemistry 282 (20): 15103-15113 May 18 2007 Pubmed
29. Identification of novel amplification gene targets in mouse and human breast cancer at a syntenic cluster mapping to mouse ch8A1 and human ch13q34
    Abba MC, Fabris VT, Hu YH, et al.
    Cancer Research 67 (9): 4104-4112 May 1 2007 Pubmed
30. Graph-based identification of cancer signaling pathways from published gene expression signatures using PubLiME
    Finocchiaro G, Mancuso FM, Cittaro D, et al.
    Nucleic Acids Research 35 (7): 2343-2355 Apr 2007 Pubmed
31. CCR2 expression correlates with prostate cancer progression
    Lu Y, Cai Z, Xiao GZ, et al.
    Jrl of Cellular Biochemistry 101 (3): 676-685 JUN 1 2007Pubmed
32. Mass spectrometry-based “omics” technologies in cancer diagnostics
    Zhang XW, Wei D, Yap Y, et al.
    Mass Spectrometry Rvws 26 (3): 403-431 MAY-JUN 2007 Pubmed
33. GCIP/CCNDBP1, a helix-loop-helix protein, suppresses tumorigenesis
    Ma WB, Stafford LJ, Li DL, et al.
    Jrl of Cellular Biochemistry 100 (6): 1376-1386 APR 15 2007 Pubmed
34. Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma
    Chen GA, Wang XJ, Yu JJ, et al.
    Cancer Research 67 (7): 3461-3467 APR 1 2007 Pubmed
35. 5-aza-2 ‘-deoxycytidine delays androgen-independent disease and improves survival in the transgenic adenocarcinoma of the mouse prostate mouse model of prostate cancer
    Zorn CS, Wojno KJ, McCabe MT, et al.
    Clinical Cancer Research 13 (7): 2136-2143 APR 1 2007 Pubmed
36. Feature selection and molecular classification of cancer using genetic programming
    Yu JJ, Yu JD, Almal AA, et al.
    Neoplasia 9 (4): 292-U16 APR 2007 Pubmed
37. Role of the chromobox protein CBX7 in lymphomagenesis
    Scott CL, Gil J, Hernando E, et al.
    Proceedings of The National Academy of Sciences of The United States of America 104 (13): 5389-5394 MAR 27 2007 Pubmed
38. Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor
    Stabile H, Mitola S, Moroni E, et al.
    Blood 109 (5): 1834-1840 MAR 1 2007 Pubmed
39. LRIG-inhibitors of growth factor signalling - double-edged swords in human cancer?
    Hedman H, Henriksson R
    European Journal of Cancer 43 (4): 676-682 MAR 2007 Pubmed
40. Identification of functional cell adhesion molecules with a potential role in metastasis by a combination of in vivo phage display and in silico analysis
    Sadanandam A, Varney ML, Kinarsky L, et al.
    Omics-a Jrl of Integrative Biology 11 (1): 41-57 MAR 2007 Pubmed
41. Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1
    Rody A, Holtrich U, Gaetje R, et al.
    Clinical Cancer Research 13 (4): 1115-1122 FEB 15 2007 Pubmed
42. Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma
    Podar K, Raab MS, Tonon G, et al.
    Cancer Research 67 (4): 1680-1688 FEB 15 2007 Pubmed
43. Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion
    Lin KY, Lu D, Hung CF, et al.
    Cancer Research 67 (4): 1832-1841 FEB 15 2007 Pubmed
44. TGFBR3 loss and consequences in prostate cancer
    Sharifi N, Hurt EM, Kawasaki BT, et al.
    Prostate 67 (3): 301-311 FEB 15 2007 Pubmed
45. DNA microarray technology in toxicogenomics of aquatic models: Methods and applications
    Ju ZL, Wells MC, Walter RB
    Comparative Biochemistry & Physiology C-toxicology & Pharmacology 145 (1): 5-14 Sp. Iss. SI FEB 2007 Pubmed
46. From bytes to bedside: Data integration and computational biology for translational cancer research
    Mathew JP, Taylor BS, Bader GD, et al.
    Plos Computational Biology 3 (2): 153-163 FEB 2007 Pubmed
47. Computational prediction of cancer- gene function
    Pingzhao Hu, Gary Bader, Dennis A. Wigle and Andrew Emili
    Nature Reviews/Cancer. 2007 Jan; vol 7:23 NPG
48. Chromosomal deletions in bladder cancer: Shutting down pathways
    Abraham R, Pagano F, Gomella LG, et al.
    Frontiers In Bioscience 12: 826-838 JAN 1 2007 Pubmed
49. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice
    Sotillo R, Hernando E, Diaz-Rodriguez E, et al.
    Cancer Cell 11 (1): 9-23 JAN 2007 Pubmed
50. Targeting cell cycle kinases for cancer therapy
    de Carcer G, de Castro IP, Malumbres M
    Current Medicinal Chemistry 14 (9): 969-985 2007 Pubmed
51. A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas
    Assou S, Le Carrour T, Tondeur S, et al.
    Stem Cells 25 (4): 961-973 2007 Pubmed
52. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
    Yen L, Cao ZW, Wu XL, et al.
    Cancer Research 2006 Dec; 66 (23): 11279-11286. Pubmed
53. Resources for integrative systems biology: from data through databases to networks and dynamic system models.
    Ng A, Bursteinas B, Gao QO, et al.
    Briefings in Bioinformatics 2006 Dec; 7 (4): 318-330. Pubmed
54. Positional expression profiling indicates candidate genes in deletion hotspots of hepatocellular carcinoma.
    Chan KYY, Lai PBS, Squire JA, et al.
    Modern Pathology 2006 Dec.; 19 (12): 1546-1554. Pubmed
55. The HBP1 transcriptional repressor participates in RAS-induced premature senescence.
    Zhang XW, Kim J, Ruthazer R, et al.
    Molecular an Cellular Biology 2006 Nov.; 26 (22): 8252-8266. Pubmed
56. A Novel Role of Myosin VI in Human Prostate Cancer.
    Dunn TA, Chen S, Faith DA, Hicks JL, Platz EA, Chen Y, Ewing CM, Sauvageot J, Isaacs WB, De Marzo AM, Luo J
    American J Pathology. 2006 Nov; 169(5):1843-54. Pubmed
57. Comparative microarray analysis.
    Larsson O, Wennmalm K, Sandberg R
    Omics-A Journal of Integrative Biology 2006 Sep; 10 (3): 381-397.Pubmed
58. Cep55, a microtubule-bundling protein, associates with centralspindlin to control the midbody integrity and cell abscission during cytokinesis.
    Zhao WM, Seki A, Fang GW.
    Molecular Biology of the Cell 2006 Sep; 17 (9): 3881-3896. Pubmed
59. The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3.
    Cloos PA, Christensen J, Agger K, Maiolica A, Rappsilber J, Antal T, Hansen KH, Helin K.
    Nature. 2006 Jul 20;442(7100):307-11.
60. Comprehensive analysis of the expression of the metastasis-associated gene 1 in human neoplastic tissue.
    Hofer MD, Tapia C, Browne TJ, Mirlacher M, Sauter G, Rubin MA.
    Arch Pathol Lab Med. 2006 Jul;130(7):989-96. Pubmed
61. CCL2 is a potent regulator of prostate cancer cell migration and proliferation.
    Loberg RD, Day LL, Harwood J, Ying C, St John LN, Giles R, Neeley CK, Pienta KJ.
    Neoplasia. 2006 Jul; 8(7):578-86.
62. Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma.
    Guo L, Ma Y, Ward R, Castranova V, Shi X, Qian Y.
    Clinical Cancer Res. 2006 Jun 1;12(11 Pt 1):3344-54.
63. Regulation of cell proliferation by the antizyme inhibitor: evidence for an antizyme-independent mechanism.
    Kim SW, Mangold U, Waghorne C, Mobascher A, Shantz L, Banyard J, Zetter BR.
    J Cell Science. 2006 Jun 15;119(Pt 12):2583-91.
64. Identical probes on different high-density oligonucleotide microarrays can produce different measurements of gene expression.
    Zhang L, Yoder SJ, Enkemann SA.
    BMC Genomics 2006 Jun; 7: Art. No. 153.
65. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.
    Yoshimoto M, Joshua AM, Chilton-Macneill S, Bayani J, Selvarajah S, Evans AJ, Zielenska M, Squire JA.
    Neoplasia. 2006 Jun;8(6):465-9.
66. Identification of genes expressed differentially in an in vitro human lung carcinogenesis model.
    Lacroix L, Feng G, Lotan R.
    Cancer Biology & Therapy 2006 Jun; 5 (6): 665-673.
67. Methylation of the ASC gene promoter is associated with aggressive prostate cancer.
    Collard RL, Harya NS, Monzon FA, Maier CE, O’Keefe DS.
    Prostate. 2006 May 15;66(7):687-95
68. Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma.
    Zhang L, Huang J, Yang N, Liang S, Barchetti A, Giannakakis A, Cadungog MG, O’Brien-Jenkins A, Massobrio M, Roby KF, Katsaros D, Gimotty P, Butzow R, Weber BL, Coukos G.
    Cancer Res. 2006 May 1;66(9):4627-35
69. Functional screening for proapoptotic genes by reverse transfection cell array technology.
    Mannherz O, Mertens D, Hahn M, Lichter P.
    Genomics. 2006 May;87(5):665-72.
70. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues.
    Miller SJ, Rangwala F, Williams J, Ackerman P, Kong S, Jegga AG, Kaiser S, Aronow BJ, Frahm S, Kluwe L, Mautner V, Upadhyaya M, Muir D, Wallace M, Hagen J, Quelle DE, Watson MA, Perry A, Gutmann DH, Ratner N.
    Cancer Res. 66, 2584-2591, Mar 1, 2006.
71. Low pH induces co-ordinate regulation of gene expression in oesophageal cells.
    Duggan SP, Gallagher WM, Fox EJ, Abdel-Latif MM, Reynolds JV, Kelleher D.
    Carcinogenesis. 2006 Feb;27(2):319-27.
72. PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer.
    Vanaja DK, Ballman KV, Morlan BW, Cheville JC, Neumann RM, Lieber MM, Tindall DJ, Young CY.
    Clinical Cancer Res. 2006 Feb . 15;12(4):1128-36.
73. Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients.
    Henrich KO, Fischer M, Mertens D, Benner A, Wiedemeyer R, Brors B, Oberthuer A, Berthold F, Wei JS, Khan J, Schwab M, Westermann F.
    Clinical Cancer Res. 2006 Jan 1;12(1):131-8.
74. Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53.
    Zalcenstein A, Weisz L, Stambolsky P, Bar J, Rotter V, Oren M.
    Oncogene. 2006 Jan 19;25(3):359-69.
75. Defining aggressive prostate cancer using a 12-gene model.
    Bismar TA, Demichelis F, Riva A, et al.
    Neoplasia 2006 Jan; 8 (1): 59-68.
76. Molecular markers for discrimination of benign and malignant follicular thyroid tumors.
    Fryknas M, Wickenberg-Bolin U, Goransson H, Gustafsson MG, Foukakis T, Lee JJ, Landegren U, Hoog A, Larsson C, Grimelius L, Wallin G, Pettersson U, Isaksson A.
    Tumor Biol. 2006;27(4):211-20.
77. Molecular analysis of minimally invasive follicular carcinomas by gene profiling.
    Lubitz CC, Gallagher LA, Finley DJ, Zhu B, Fahey TJ
    Surgery. 2005 Dec;138(6):1042-8.
78. A review of the past, present, and future directions of neoplasia.
    Rehemtulla, A., and Ross, B. D.
    Neoplasia 2005 Dec; 7(12), 1039-1046.
79. The octamer binding transcription factor Oct-1 is a stress sensor.
    Tantin D, Schild-Poulter C, Wang V, Hache RJ, Sharp PA.
    Cancer Res. 2005 Dec 1;65(23):10750-8.
80. Two different global gene expression profiles in cancer cell lines established from etiologically different oral carcinomas.
    Ruutu, M., Johansson, B., Grenman, R., Syrjanen, S.
    Oncol Rep 2005 Dec; 14(6), 1511-1517.
81. Overlapping gene expression in fetal mouse intestine development and human colorectal cancer.
    Hu M, Shivdasani RA.
    Cancer Res. 2005 Oct 1;65(19):8715-22.
82. Identification of MMP-15 as an anti-apoptotic factor in cancer cells.
    Abraham R, Schafer J, Rothe M, Bange J, Knyazev P, Ullrich A.
    J Biol Chem. 2005 Oct 7;280(40):34123-32.
83. List of lists-annotated (LOLA): a database for annotation and comparison of published microarray gene lists.
    Cahan, P., Ahmad, A. M., Burke, H., Fu, S., Lai, Y., Florea, L., Dharker, N., Kobrinski, T., Kale, P., and McCaffrey, T. A.
    Gene 2005 Oct; 360, 78-82.
84. Mechanisms of PECAM-1-mediated cytoprotection and implications for cancer cell survival.
    Bergom C, Gao C, Newman PJ.
    Leuk Lymphoma. 2005 Oct; 46(10):1409-21.
85. Robust prostate cancer marker genes emerge from direct integration of inter-study microarray data.
    Xu, L., Tan, A. C., Naiman, D. Q., Geman, D., and Winslow, R. L.
    Bioinformatics 2005 Oct; 21, 3905-3911.
86. Prostate cancer cells promote osteoblastic bone metastases through Wnts.
    Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET.
    Cancer Res. 2005 Sep 1;65(17):7554-60.
87. Functional profiling: from microarrays via cell-based assays to novel tumor relevant modulators of the cell cycle.
    Arlt D, Huber W, Liebel U, Schmidt C, Majety M, Sauermann M, Rosenfelder H, Bechtel S, Mehrle A, Bannasch D, Schupp I, Seiler M, Simpson JC, Hahne F, Moosmayer P, Ruschhaupt M, Guilleaume B, Wellenreuther R, Pepperkok R, Sultmann H, Poustka A, Wiemann S.
    Cancer Res. 2005 Sep; 65(17):7733-42.
88. Emerging issues of the expression profiling technologies for the study of gynecologic cancer.
    Pappa, K. I., and Anagnou, N. P.
    Am J Obstet Gynecol 2005 Sep.;. 193, 908-918.
89. TP53 mutations are associated with a particular pattern of genomic imbalances in breast carcinomas.
    Kleivi K, Diep CB, Pandis N, Heim S, Teixeira MR, Lothe RA.
    J Pathol. 2005 Sep ; 207(1):14-9.
90. Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker?
    Hashimoto, Y., Skacel, M., and Adams, J. C.
    Int J Biochem Cell Biol 2005 Sep; 37, 1787-1804.
91. From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response.
    Laganiere, J., Deblois, G., Lefebvre, C., Bataille, A. R., Robert, F., and Giguere, V.
    Proc Natl Acad Sci USA 2005 Aug; 102,11651-11656.
92. GEMS: a system for automated cancer diagnosis and biomarker discovery from microarray gene expression data.
    Statnikov, A., Tsamardinos, I., Dosbayev, Y., and Aliferis, C. F.
    Int J Med Inform 2005 Aug; 74, 491-503.
93. Storing, linking, and mining microarray databases using SRS.
    Veldhoven, A., de Lange, D., Smid, M., de Jager, V., Kors, J. A., and Jenster, G.
    BMC Bioinformatics 2005 Jul; 6, 192.
94. Give lipids a START: the StAR-related lipid transfer (START) domain in mammals.
    Alpy, F., and Tomasetto, C.
    J Cell Science 2005 Jul; 118, 2791-2801.
95. High-resolution genomic profiles of human lung cancer.
    Tonon G, Wong KK, Maulik G, Brennan C, Feng B, Zhang Y, Khatry DB, Protopopov A, You MJ, Aguirre AJ, Martin ES, Yang Z, Ji H, Chin L, Depinho RA.
    Proc Natl Acad Sci U S A. 2005 Jul; 102(27):9625-30.
96. Microarray-based classification of diffuse large B-cell lymphoma.
    Poulsen CB, Borup R, Nielsen FC, Borregaard N, Hansen M, Gronbaek K, Moller MB, Ralfkiaer E.
    European J Haematology. 2005 Jun; 74(6):453-65.
97. A genetic screen for candidate tumor suppressors identifies REST.
    Westbrook, T. F., Martin, E. S., Schlabach, M. R., Leng, Y., Liang, A. C., Feng, B., Zhao, J. J., Roberts, T. M., Mandel, G., Hannon, G. J., et al.
    Cell 2005 Jun; 121, 837-848.
98. Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers.
    Haruki, N., Kawaguchi, K. S., Eichenberger, S., Massion, P. P., Olson, S., Gonzalez, A., Carbone, D. P., and Dang, T. P.
    Cancer Research 2005 May; 65, 3555-3561.
99. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification.
    Bergmann, S., Royer-Pokora, B., Fietze, E., Jurchott, K., Hildebrandt, B., Trost, D., Leenders, F., Claude, J. C., Theuring, F., Bargou, R., et al.
    Cancer Research 2005 May; 65, 4078-4087.
100. Ku is a novel transcriptional recycling coactivator of the androgen receptor in prostate cancer cells.
     Mayeur, G. L., Kung, W. J., Martinez, A., Izumiya, C., Chen, D. J., and Kung, H. J.
     J Biol Chem 2005 Mar; 280, 10827-10833.
101. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
     Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, Richards W, Sugarbaker D, Husain AN, Christensen JG, Salgia R.
     Cancer Research. 2005 Feb 15; 65(4):1479-88.
102. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.
     Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orlowska-Volk M, Bauknecht T, Park TW, Jonat W, Jacobsen A, Sehouli J, Luttges J, Krajewski M, Krajewski S, Reed JC, Arnold N, Hampton GM.
     Oncogene. 2005 Feb 3;24(6):1053-65.
103. A database for tracking toxicogenomic samples and procedures.
     Bao, W., Schmid, J. E., Goetz, A. K., Ren, H., and Dix, D. J.
     Reproductive Toxicology 2005 Jan.-Feb.; 19, 411-419.
104. L2L: a simple tool for discovering the hidden significance in microarray expression data.
     Newman, J. C., and Weiner, A. M.
     Genome Biol 2005. 6(9), R81.
105. The tumor protein D52 family: many pieces, many puzzles.
     Boutros, R., Fanayan, S., Shehata, M., and Byrne, J. A.
     Biochem Biophys Res Commun 2004 Dec; 325, 1115-1121.
106. Splicing factors are differentially expressed in tumors.
     Kirschbaum-Slager N, Lopes GM, Galante PA, Riggins GJ, de Souza SJ.
     Genet Mol Res. 2004 Dec 30;3(4):512-20.
107. QA/QC: challenges and pitfalls facing the microarray community and regulatory agencies.
     Shi, L., Tong, W., Goodsaid, F., Frueh, F. W., Fang, H., Han, T., Fuscoe, J., and Casciano, D. A.
     Expert Rev Mol Diagnostics 2004 Nov; 4, 761-777.
108. Vitamin D3 modulated gene expression patterns in human primary normal and cancer prostate cells.
     Guzey M, Luo J, Getzenberg RH.
     J Cell Biochem. 2004 Oct 1;93(2):271-85.
109. Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin.
     Wagner KW, Sapinoso LM, El-Rifai W, Frierson HF, Butz N, Mestan J, Hofmann F, Deveraux QL, Hampton GM.
     Oncogene 2004 Aug.; 23 (39): 6621-6629.
110. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck.
     Ginos MA, Page GP, Michalowicz BS, Patel KJ, Volker SE, Pambuccian SE, Ondrey FG, Adams GL, Gaffney PM.
     Cancer Res. 2004 Jan 1;64(1):55-63.

Download a complete list of references.